GlassScriptPhysician profile
Glenn Gandelman
NPI 1033117437
$10,338.81
in general payments reported to CMS, 2019-2025
57 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $292 · 2021: $704 · 2022: $1,720 · 2023: $2,567 · 2024: $2,047 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,642.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,246.27 | 2019-2025 | |
| Abbvie INC. | $1,089.77 | 2022-2025 | |
| Exact Sciences Corporation | $703.10 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $654.30 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $643.69 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.13 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $410.11 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $352.49 | 2019-2024 | Farxiga, Fasenra |
| Idorsia Pharmaceuticals US INC | $347.25 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $314.06 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $293.03 | 2019-2024 | Camzyos, Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $283.90 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $259.69 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $255.92 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $247.61 | 2021-2025 | Verquvo, Belsomra, M-M-R II |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $236.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $233.57 | 2019-2022 | |
| Pfizer INC. | $197.50 | 2019-2025 | |
| Abbott Laboratories | $162.05 | 2021-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $154.74 | 2021-2024 | Nexletol |
| Qol Medical, LLC | $138.55 | 2022-2023 | Sucraid |
| Lilly USA, LLC | $128.41 | 2024-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $122.11 | 2023-2025 | |
| Bausch Health US, LLC | $115.45 | 2024-2025 | Aplenzin, Wellbutrin |
| Sanofi-Aventis U.S. LLC | $114.32 | 2019-2021 | |
| Corium, LLC | $84.77 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $70.03 | 2022 | |
| Antares Pharma, INC. | $67.93 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.95 | 2019-2023 | Lifevest |
| Upsher-Smith Laboratories LLC | $60.97 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $56.81 | 2023 | Inpefa |
| Medtronic, INC. | $53.84 | 2024 | Corevalve Evolut R |
| Nestle Healthcare Nutrition INC. | $52.78 | 2023 | |
| Boston Scientific Corporation | $49.38 | 2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $42.84 | 2025 | Onpattro, Amvuttra |
| Otsuka America Pharmaceutical, INC. | $40.71 | 2023-2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $36.78 | 2024 | Opsumit, Uptravi |
| Baxter Healthcare | $29.89 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Biohaven Pharmaceutical Holding Company LTD. | $28.72 | 2022 | |
| Gilead Sciences, INC. | $26.92 | 2019 | |
| Lundbeck LLC | $26.66 | 2022 | |
| Impel Pharmaceuticals INC. | $24.81 | 2022 | |
| Cleerly, INC. | $24.04 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Almatica Pharma LLC | $23.02 | 2025 | Loreev Xr |
| Ironwood Pharmaceuticals, INC | $22.05 | 2023 | Linzess |
| Jazz Pharmaceuticals INC. | $21.24 | 2022 | |
| Itamar Medical INC | $21.19 | 2025 | Watchpatone |
| Allergan, INC. | $20.56 | 2019 | |
| Dexcom, INC. | $20.08 | 2025 | Dexcom G6 Transmitter |
| Optinose US, INC. | $19.00 | 2025 | |
| Vivaquant INC, Dba Rhythm Express | $18.78 | 2025 | Rhythm Express |
| Azurity Pharmaceuticals, INC. | $18.00 | 2023 | Horizant |
| Phathom Pharmaceuticals, INC. | $17.14 | 2025 | Voquezna |
| Endo Pharmaceuticals INC. | $15.22 | 2022 | |
| Phadia US INC. | $14.12 | 2025 | Immunocap |
| Regeneron Healthcare Solutions, INC. | $11.97 | 2019 | |
| Bardy Diagnostics, INC. | $7.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Gandelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.